28.89

5.94% 1.62

After Hours: 28.89

Collegium Pharmaceutical Inc (COLL)

Overview News Price History Option Chain Financials Discussions Forecast

Collegium Pharmaceutical Inc stock is traded at $28.89, with a volume of 561.66K. It is up +5.94% in the last 24 hours and up +9.56% over the past month. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Previous Close:

$27.27

Open:

$29.66

24h Volume:

561.66K

Relative Volume:

1.48

Market Cap:

$888.44M

Revenue:

$566.77M

Net Income/Loss:

$48.16M

P/E Ratio:

24.28

EPS:

1.19

Net Cash Flow:

$274.29M

1W Performance:

+4.48%

1M Performance:

+9.56%

6M Performance:

-10.17%

1Y Performance:

-23.69%

1-Day Range:

$27.84

$29.66

1-Week Range:

$26.72

$29.66

52-Week Range:

$23.23

$42.29

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name

Collegium Pharmaceutical Inc

Sector

Healthcare (1153)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

781-713-3699

Address

100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA

Employee

357

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

COLL's Discussions on Twitter

Compare COLL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COLL Collegium Pharmaceutical Inc	28.89	888.44M	566.77M	48.16M	274.29M	1.19
ZTS Zoetis Inc	159.27	70.23B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.74	48.23B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.36	48.22B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.93	18.57B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	301.42	13.29B	2.76B	1.11B	898.10M	22.77

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Upgrade	Needham	Hold → Buy
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-07-24	Upgrade	Jefferies	Hold → Buy
May-10-24	Downgrade	Needham	Buy → Hold
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-24	Downgrade	Jefferies	Buy → Hold
Aug-25-23	Reiterated	Needham	Buy
May-02-23	Resumed	Jefferies	Buy
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Jul-14-20	Initiated	BWS Financial	Sell
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy
Oct-30-19	Reiterated	Needham	Buy
May-03-19	Resumed	H.C. Wainwright	Buy
Apr-12-19	Resumed	Janney	Buy
Mar-20-19	Initiated	SunTrust	Hold
Jan-16-19	Reiterated	Needham	Buy
Mar-08-18	Reiterated	H.C. Wainwright	Buy
Feb-07-18	Reiterated	Needham	Buy
Dec-05-17	Reiterated	Needham	Buy
Sep-11-17	Initiated	H.C. Wainwright	Buy
May-11-17	Reiterated	Needham	Buy
Sep-13-16	Initiated	Gabelli & Co	Buy
Jun-01-15	Initiated	Jefferies	Buy
Jun-01-15	Initiated	Needham	Buy
Jun-01-15	Initiated	Piper Jaffray	Overweight

View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

08:24 AM

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2025 Earnings Call Transcript - Insider Monkey

08:24 AM

04:54 AM

Collegium pharmaceutical targets $135M in Jornay PM revenue for 2025 amid sales force expansion - MSN

04:54 AM

02:28 AM

Collegium Pharmaceutical (COLL) Sees Price Target Increase by Pi - GuruFocus

02:28 AM

May 09, 2025

Collegium Pharmaceutical’s Earnings Call Highlights Growth and Strategic Initiatives - TipRanks

May 09, 2025

Collegium Pharmaceutical (COLL) Price Target Increased by Piper Sandler | COLL Stock News - GuruFocus

May 09, 2025

Earnings call transcript: Collegium Pharmaceutical sees strong Q1 2025 growth - Investing.com India

May 09, 2025

Collegium Pharmaceutical, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:COLL) - Seeking Alpha

May 09, 2025

May 08, 2025

Pacer Advisors, Inc. Significantly Reduces Holdings in Collegium Pharmaceutical Inc. - GuruFocus

May 08, 2025

Pacer Advisors, Inc. Reduces Stake in Collegium Pharmaceutical Inc - GuruFocus

May 08, 2025

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations - Yahoo Finance

May 08, 2025

Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

May 08, 2025

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance

May 08, 2025

Collegium Pharmaceutical Reports 23% Revenue Increase - TipRanks

May 08, 2025

COLL Reaffirms FY25 Adjusted EBITDA Outlook and Highlights Strat - GuruFocus

May 08, 2025

COLLEGIUM PHARMACEUTICAL Earnings Results: $COLL Reports Quarterly Earnings - Nasdaq

May 08, 2025

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire

May 08, 2025

May 07, 2025